An avalanche of lawsuits filed against Bayer in Missouri is pitting the chemical maker against trial attorneys and cancer patients.

Berenberg Bank analyst Sebastian Bray maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €22.00. The ...

Bayer pleaded with Missouri lawmakers Thursday to pass legislation critics say would shield the company from lawsuits ...

Acquisition of Iprovalicarb and Triadinenol grants Dhanuka access to markets in over 20 countries from LATAM, EMEA, ASIA, and ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Bayer (0P6S – Research Report), with a price target of ...

As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch of one of the ...

“Incremental celebrates the strong results of our collaboration with Bayer and Skai,” said David Pollet, CEO of Incremental. “Integrating incrementally measurement directly into media activation ...

Chemical company Monsanto — owned by Bayer — was found liable this week by a jury for harm caused to students and parents at ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...